日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression

对良性和恶性前列腺中的雄激素受体进行逐个细胞量化,有助于更好地了解与癌症发生和进展相关的变化

Seta Derderian, Tarik Benidir, Eleonora Scarlata, Turki Altaylouni, Lucie Hamel, Fatima Zahra Zouanat, Fadi Brimo, Armen Aprikian, Simone Chevalier

Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network

NF-κB p65 在前列腺癌中的预后价值的验证:使用加拿大前列腺癌生物标志物网络的大型多机构队列进行的回顾性研究

Andrée-Anne Grosset, Véronique Ouellet, Christine Caron, Gabriela Fragoso, Véronique Barrès, Nathalie Delvoye, Mathieu Latour, Armen Aprikian, Alain Bergeron, Simone Chevalier, Ladan Fazli, Neil Fleshner, Martin Gleave, Pierre Karakiewicz, Louis Lacombe, Jean-Baptiste Lattouf, Theodorus van der Kwas

Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer

核 mTOR 充当前列腺癌中雄激素信号通路的转录整合子

Étienne Audet-Walsh, Catherine R Dufour, Tracey Yee, Fatima Z Zouanat, Ming Yan, Georges Kalloghlian, Mathieu Vernier, Maxime Caron, Guillaume Bourque, Eleonora Scarlata, Lucie Hamel, Fadi Brimo, Armen G Aprikian, Jacques Lapointe, Simone Chevalier, Vincent Giguère

A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer

通过 EGFR 信号传导诱导 PPAR γ 的新机制为膀胱癌联合治疗提供了理论依据

Jose Joao Mansure, Roland Nassim, Simone Chevalier, Konrad Szymanski, Joice Rocha, Saad Aldousari, Wassim Kassouf

The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression

前列腺癌中的 16p13.3 (PDPK1) 基因组增益:在疾病进展中的潜在作用

Khalil A Choucair, Karl-Philippe Guérard, Joshua Ejdelman, Simone Chevalier, Maisa Yoshimoto, Eleonora Scarlata, Ladan Fazli, Kanishka Sircar, Jeremy A Squire, Fadi Brimo, Isabela W Cunha, Armen Aprikian, Martin Gleave, Jacques Lapointe